Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite to manage access for both oral and office-administered oncology agents, payers struggle with which tactics to implement without sacrificing patient outcomes. Pharmaceutical companies should expect to see changes in payer management for oncology over the next 2-3 years. In a recent article, the NAVLIN Insights team outlines payer access management in oncology today and takes a closer look at how access will evolve in the coming years, including the impact of the Inflation Reduction Act and which brands may […]
EVERSANA’s deep bench of oncology experts leverage their extensive industry experience to inform strategies and deliver services that pave the way to commercial success. In an effort to share expert knowledge and help manufacturers understand the complexities of commercialization for new oncology therapies, EVERSANA developed a robust library of resources.